Alaleh Nouri, who serves as executive vice president and chief legal officer for Procept BioRobotics Corp (NASDAQ: PRCT), executed a sale of 304 shares of common stock on March 17, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at $28.1532 per share, producing a total reported transaction value of $8,558.
Following the disposition, Nouri directly holds 110,717 shares of Procept. Company filings indicate the stock sale was completed to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
Procept's share price has come under notable pressure over the last year, declining 54.72%. At the time of the filing, the stock was trading at $25.68, a level below the price at which Nouri sold her shares.
Market commentary included in the filing references InvestingPro analysis, which indicates the company may be undervalued at current prices. Investors are pointed to PRCT's Pro Research Report available through InvestingPro, which covers this company and more than 1,400 other U.S. equities.
Operationally, Procept announced the international introduction of its HYDROS Robotic System in the United Kingdom, and stated it plans further expansion in 2026. The HYDROS System is intended to provide Aquablation therapy for the treatment of benign prostatic hyperplasia.
Several brokerages have recently issued guidance and updates on the company. Baird initiated coverage with a Neutral rating and set a price target of $30.00. Truist Securities adjusted its price target to $30 from $47 while maintaining a Buy rating, citing lower forecasts for 2027. TD Cowen reiterated a Buy rating with a $34.00 price target, noting the company is working to justify recent commercial changes.
In addition to commercial and coverage developments, Procept expanded its board by appointing Daniel Puckett as a director and member of the audit committee. Puckett will serve as a Class III director, with a term that expires in 2027.
Taken together, the insider sale, the company's UK product launch plans, shifts in analyst price targets, and a change to the board reflect a period of active operational and strategic movement at Procept BioRobotics.
Disclosure: